Citi believes today’s weakness in Arcellx (ACLX) is “an overreaction to the highly preliminary” Phase 1 inMMyCAR data for Kelonia Therapeutics’ KLN-1010. While the achievement of MRD-negativity is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback